Treatments in Development
Pre-clinical and early-stage drug candidates for erythromelalgia that are not yet in full clinical trials. These include gene therapies, sodium channel blockers, and TRPV1 inhibitors in various stages of development.
Current Candidates
3 treatments currently in development for erythromelalgia, from early preclinical research to Phase 2-ready candidates.
XEN-D0501
Transient receptor potential vanilloid 1 (TRPV1) antagonist that down-regulates neurogenic inflammation to address pain and inflammatory conditions.
Key Highlights
- Clinical trial application expected H1 2026
- Completed Phase 2a trials in obesity/diabetes showing good tolerability
- Animal studies demonstrated excellent safety after 13 weeks at high doses
- Estimated 3-year timeline to potential market approval
- 7-year regulatory exclusivity in US if approved
Development Status
Phase 2a data (diabetes): Significantly enhanced endogenous insulin response and reduced cardiovascular biomarker ANP vs placebo
NT-Z001
De-immunized epigenetic therapy using AI-enabled platform to precisely downregulate SCN9A gene expression without altering DNA sequence. Targets the Nav1.7 sodium channel encoded by SCN9A.
Key Highlights
- Received $4M CIRM grant (February 2025) for IND-enabling studies
- Novel epigenetic editor technology - modifies gene expression without changing DNA
- Partnership with Charles River for AAV vector manufacturing
- Targets root cause (SCN9A gain-of-function mutation)
- AI-enabled platform for precision gene regulation
- Potential for long-lasting pain relief
Development Status
Preclinical studies ongoing; IND application in preparation
STC-004
Nav1.8-selective inhibitor being developed for chronic pain conditions. While not specifically targeting erythromelalgia, Nav1.8 plays a role in peripheral pain signaling.
Key Highlights
- Acquired by Eli Lilly May 2025 (up to $1B deal)
- Phase 2 ready for chronic pain indications
- Nav1.8 channel is expressed in peripheral pain neurons
- Non-opioid mechanism for pain management
- Major pharma backing (Lilly)
Development Status
Phase 2 ready; primary indication is broader chronic pain (not EM-specific)
Note: These treatments are in early development stages. Most are years away from approval. For active clinical trials, see the Clinical Trials page.
Pipeline data is manually curated from press releases, company announcements, and scientific publications. Last updated: April 2026.